Search research articles
Contact Us
Filters
Showing results (111-120 of 190) with videos related to
Page
of 19
Sort By:
Public Health Genomics
|
April 22, 2010
Stakeholder perspectives on a risk-benefit framework for genetic testing
Joshua A Roth, Louis P Garrison, Wylie Burke, et al.
Journal of Medical Economics
|
March 26, 2010
The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment
Mindy M Cheng, Rafael Alfonso, Jennie H Best, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 2, 2008
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model
Beate Sander, Azhar Nizam, Louis P Garrison, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 21, 2015
The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer
Louis P Garrison, Joseph B Babigumira, Anthony Masaquel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
November 28, 2021
Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data
Woojung Lee, Meng Li, William B Wong, et al.
Journal of Medical Economics
|
May 4, 2019
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study
Gregory F Guzauskas, Erqi L Pollom, Volker W Stieber, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
July 28, 2012
Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy
Gregory F Guzauskas, Louis P Garrison, Jacquie Stock, et al.
Journal of Managed Care & Specialty Pharmacy
|
August 25, 2021
Real-world evidence for option value in metastatic melanoma
William B Wong, Tu My To, Meng Li, et al.
Plos One
|
January 31, 2025
A prospective model of the potential clinical and economic impact of cervical cancer screening supported by a mobile phone app
Fredrick Chite Asirwa, Brian W Bresnahan, Faith Yego, et al.
Diabetes Care
|
January 29, 2011
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment
Jennie H Best, Richard R Rubin, Mark Peyrot, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 190) with videos related to
Sort By:
Page
of 19
Public Health Genomics
|
April 22, 2010
Stakeholder perspectives on a risk-benefit framework for genetic testing
Joshua A Roth, Louis P Garrison, Wylie Burke, et al.
Journal of Medical Economics
|
March 26, 2010
The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment
Mindy M Cheng, Rafael Alfonso, Jennie H Best, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 2, 2008
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model
Beate Sander, Azhar Nizam, Louis P Garrison, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 21, 2015
The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer
Louis P Garrison, Joseph B Babigumira, Anthony Masaquel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
November 28, 2021
Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data
Woojung Lee, Meng Li, William B Wong, et al.
Journal of Medical Economics
|
May 4, 2019
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study
Gregory F Guzauskas, Erqi L Pollom, Volker W Stieber, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
July 28, 2012
Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy
Gregory F Guzauskas, Louis P Garrison, Jacquie Stock, et al.
Journal of Managed Care & Specialty Pharmacy
|
August 25, 2021
Real-world evidence for option value in metastatic melanoma
William B Wong, Tu My To, Meng Li, et al.
Plos One
|
January 31, 2025
A prospective model of the potential clinical and economic impact of cervical cancer screening supported by a mobile phone app
Fredrick Chite Asirwa, Brian W Bresnahan, Faith Yego, et al.
Diabetes Care
|
January 29, 2011
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment
Jennie H Best, Richard R Rubin, Mark Peyrot, et al.
Page
of 19